22 results
Zie pagina 39-40 van het protocol MO22923 versie 2, 26 Mei 2011
To provide clinical management and, if required, treatment to subjects who at their concluding HPV-015 study visit displayed normal cervical cytology but tested positive for oncogenic HPV infection or who were pregnant at their concluding visit of…
Primary: • Demonstrate superior efficacy (increased progression-free survival [PFS]) of MEK162 vs. physician*s choice of selected chemotherapies (liposomal doxorubicin, paclitaxel and topotecan)Key Secondary: • Demonstrate superior efficacy (…
The primary objective of this study is to establish and compare the rates of vaginal relapse in patients with high-intermediate risk endometrial carcinoma treated with vaginal brachytherapy (standard versus reduced brachytherapy dose schedule of 21…
The key objective of the study is to prove that trabectedin (Yondelis) and PLD prolong overall survival versus carboplatin + PLD, in patients with progressive ovarian cancer 6 to 12 months after completing previous platinum based chemotherapy.As…
To determine the clinical effectiveness of adjuvant therapy given to all unstaged (no lymph node dissection) high risk stage 1 endometrial cancer, compared with only node positive (staged) cases as judged by full lymph node dissection.
There is still no level I-II evidence for cytoreductive surgery in recurrent ovarian cancer. This is also the conclusion of a Cochrane Review of Galaal et al. published in June 2010. The most active chemotherapy in platinum sensitive recurrent…
To show superiority of patupilone in overall survival compared to pegylated liposomal doxorubicin (Doxil®/Caelyx®) in taxane/platinum refractory/resistant patients with recurrentovariancancer.
To demonstrate efficacy of adjuvant combination chemotherapy in a randomized phase III trial comparing to no further treatment in the medium and high-risk node negative stage I and stage II patients.
1. To assess the feasibility of SLN identification in endometrial cancer.2. To examine in how many cases SLN biopsy provides results that will tailor adjuvant treatment3. To investigate if SLN biopsy in women with low- and intermediate-risk…
To evaluate whether a less radical surgical approach with sentinel lymph node biopsy is non-inferior to treatment with systematic pelvic lymphadenectomy.The null hypothesis is that the recurrence rate after SLN biopsy is non-inferior to the…
Primary objective:- To determine if TTFields at 200 kHz to the abdomen and pelvis with weekly paclitaxel in the treatment of recurrent ovarian cancer patients prolongs the overall survival of patients, compared to weekly paclitaxel treatment alone.…
The primary objective of this study is to examine whether MIS is non-inferior to laparotomy in terms of disease free survival (DFS) in women with advanced stage EOC that received 3 to 4 cycles of NACT.
The purpose of the study is to determine whether treatment with alpelisib in combination with olaparib can delay the time to cancer progression compared to standard-of-care chemotherapy in participants with your type of ovarian cancer known as…
Evaluate the antitumor activity of nemvaleukin alfa (*nemvaleukin*, ALKS 4230) in combination with pembrolizumab as compared with chemotherapy in patients with platinum-resistant ovarian cancerSecondary Objectives:Evaluate the antitumor activity of…
This study has been transitioned to CTIS with ID 2024-516708-40-00 check the CTIS register for the current data. The primary objective of this proof-of-concept study is to evaluate feasibility of 68Ga-tilmanocept PET/CT for SLN mapping in patients…
This study has been transitioned to CTIS with ID 2023-509049-11-00 check the CTIS register for the current data. The primary objective of this study is to evaluate the effect of HIPEC on overall survival when added to primary cytoreductive surgery…
This study has been transitioned to CTIS with ID 2023-503267-42-00 check the CTIS register for the current data. Primary:• 3 year recurrence free survival (RFS), in patients with MMRd HREC Secondary:• RFS (median and at 5 years)• OS (median, 3yr,…
This study has been transitioned to CTIS with ID 2023-506361-56-00 check the CTIS register for the current data. This study is designed to assess the efficacy and safety of pembrolizumab monotherapy compared with SoC platinum doublet chemotherapy…
Primary* To confirm the efficacy of OTL38 in combination with fluorescent light to detect additional Folate Receptor-positive (FR+) ovarian cancer lesions not detected by palpation and visualization under normal light in patients with FR+ ovarian…